CN112168855A - A composition for preparing intestinal tract and treating constipation - Google Patents
A composition for preparing intestinal tract and treating constipation Download PDFInfo
- Publication number
- CN112168855A CN112168855A CN202010851993.9A CN202010851993A CN112168855A CN 112168855 A CN112168855 A CN 112168855A CN 202010851993 A CN202010851993 A CN 202010851993A CN 112168855 A CN112168855 A CN 112168855A
- Authority
- CN
- China
- Prior art keywords
- composition
- arabinose
- preparation
- sunflower
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims description 20
- 206010010774 Constipation Diseases 0.000 title abstract description 11
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 37
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 21
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 16
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000284 extract Substances 0.000 claims description 43
- 241000208818 Helianthus Species 0.000 claims description 40
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 21
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 19
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 19
- 239000000600 sorbitol Substances 0.000 claims description 19
- 230000029142 excretion Effects 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 239000008141 laxative Substances 0.000 claims description 6
- 230000002475 laxative effect Effects 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 238000000638 solvent extraction Methods 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 241000699670 Mus sp. Species 0.000 description 11
- 239000003814 drug Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000002040 relaxant effect Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000009297 electrocoagulation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- -1 etc.) Polymers 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition for bowel preparation and treatment of constipation. Specifically, the invention provides a composition comprising a sugar alcohol and arabinose. The composition of the present invention has excellent bowel cleansing effect and patient compliance.
Description
Technical Field
The invention relates to the field of medicines, in particular to a composition for preparing intestinal tracts and treating constipation.
Background
The intestinal tract preparation methods are different, the effects are different, and the selection of the intestinal tract preparation method with good intestinal tract clearing effect, small side effect and wide application range is very important.
Although a plurality of medicines for preparing the intestinal tract exist in the prior art, such as compound polyethylene glycol electrolyte powder, magnesium sulfate, sodium sulfate, polyethylene glycol and the like, the medicines are often poor in taste and large in dosage, adverse reaction symptoms such as nausea, vomiting, abdominal distension and the like are easy to occur, an intestinal tract cleaning effect is not ideal, the effect of enteroscopy observation cannot be achieved, the repeated intestinal tract preparation process of a patient is caused, the psychology of the intestinal tract preparation before enteroscopy of the patient is influenced, the compliance of the patient is greatly reduced, the preparation effect of a medicament description cannot be achieved, and the medical burden of the enteroscopy can be increased.
Therefore, there is a need in the art to develop a bowel clearing drug with excellent bowel clearing effect and good patient compliance.
Disclosure of Invention
The invention aims to provide a bowel clearing composition containing sugar alcohol and arabinose, which has excellent bowel clearing effect and good patient compliance.
In a first aspect of the invention, there is provided a composition comprising a sugar alcohol and arabinose.
Preferably, the arabinose comprises L-arabinose.
Preferably, the sugar alcohol comprises one or more of sorbitol and mannitol.
Preferably, the weight ratio of sugar alcohol to arabinose is 1:0.5-40, preferably 1:0.5-20, more preferably 1:1-10, more preferably 1:1-8, more preferably 1: 2-6.
Preferably, the composition further comprises sunflower flower extract.
Preferably, the sunflower flower extract is dry extract.
Preferably, the weight ratio of said sugar alcohol to sunflower extract is 1:0.2-20, preferably 1:0.5-10, more preferably 1:0.8-6, more preferably 1:1-5, more preferably 1: 1-3.
Preferably, the weight ratio of the sugar alcohol to the arabinose to the sunflower extract is 1 (1-10): (0.8-6), preferably 1 (1-8): (1-5), more preferably 1 (2-6): (1-3).
Preferably, said sunflower extract is prepared by solvent extraction selected from the group consisting of: water, C1-C4 lower alcohol or C1-C4 lower alcohol aqueous solution.
Preferably, the sunflower flower extract is prepared by the following method:
extracting sunflower with aqueous solution of C1-C4 lower alcohol, filtering, concentrating the filtrate, and drying to obtain the extract.
Preferably, the sunflower flower extract is prepared by the following method:
adding 4-6 times of 70-80% (v/v) ethanol water solution into sunflower, heating and reflux extracting for 6-10 hr, filtering, concentrating the filtrate under reduced pressure, and drying to obtain dry extract, i.e. sunflower extract.
Preferably, the C1-C4 lower alcohol comprises one or more of methanol, ethanol, propanol and butanol.
Preferably, the aqueous solution of C1-C4 lower alcohol is 30-95% (v/v) aqueous ethanol, preferably 50-90% (v/v) aqueous ethanol, more preferably 60-85% (v/v) aqueous ethanol, preferably 70-80% (v/v) aqueous ethanol.
Preferably, the sugar alcohol is present in an amount of 1 to 99 wt%, preferably 10 to 90 wt%, more preferably 20 to 80 wt%, based on the total weight of the composition.
Preferably, the arabinose is present in an amount of 1 to 99 wt%, preferably 10 to 90 wt%, more preferably 20 to 80 wt%, based on the total weight of the composition.
Preferably, said sunflower extract is present in an amount of 1-99 wt%, preferably 10-90 wt%, more preferably 20-80 wt%, based on the total weight of the composition.
Preferably, the composition is a pharmaceutical composition, a food composition or a health care composition.
Preferably, the composition further comprises a pharmaceutically, food or nutraceutical acceptable carrier.
Preferably, the composition is in a solid or liquid form.
Preferably, the composition is in the form of oral preparation or injection preparation.
Preferably, the composition is in the form of tablets, capsules, oral liquid, granules, powder or syrup.
In a second aspect of the invention, there is provided the use of a composition according to the first aspect of the invention for the preparation of a composition for one or more uses selected from the group consisting of: (a) as a laxative; (b) for bowel preparation.
In a third aspect of the invention, there is provided the use of a sunflower flower extract for the preparation of a composition for one or more uses selected from the group consisting of: (i) as a laxative; (ii) for bowel preparation; (iii) it can be used for enhancing excretion and intestinal tract preparation of sugar alcohol and L-arabinose.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.
Detailed Description
The invention finds that the combination of the sorbitol and the L-arabinose, as well as the sorbitol, the L-arabinose and the sunflower flower extract has excellent synergistic effect on promoting excretion and relaxing bowel, thereby being used for treating constipation, playing a role in cathartic and also being used for intestinal tract preparation and intestinal tract related operation (such as high-frequency electrocoagulation and/or high-frequency electrosection) treatment after the intestinal tract preparation.
Term(s) for
As used herein, the terms "comprising," including, "and" containing "are used interchangeably and include not only open-ended definitions, but also semi-closed and closed-ended definitions, and include" consisting of … …, "" consisting essentially of … ….
As used herein, "sunflower" is the flower bud of the plant sunflower of the family asteraceae.
The following description of the exemplary embodiments of the present application, including various details of the embodiments of the present application to assist in understanding, should be taken as exemplary only. Accordingly, those of ordinary skill in the art will recognize that various changes and modifications of the embodiments described herein can be made without departing from the scope and spirit of the present application. Also, descriptions of well-known functions and constructions are omitted in the following description for clarity and conciseness.
Composition comprising a metal oxide and a metal oxide
The invention also provides a composition which can be a pharmaceutical composition, a food composition or a health-care product composition.
Typically, the composition comprises a sugar alcohol and arabinose.
The composition also comprises a carrier acceptable in pharmacy, food or health care products.
In the present invention, the pharmaceutically acceptable carrier is not particularly limited, and may be prepared from materials commonly used in the art, or prepared by conventional methods, or commercially available. Examples of the pharmaceutically acceptable carrier moiety are cellulose and its derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, etc.), polyols (e.g., propylene glycol, glycerin, sorbitol, etc.), emulsifiers (e.g., tween), wetting agents (e.g., sodium laurylsulfate), buffers, chelating agents, thickeners, pH adjusters, transdermal enhancers, colorants, flavors, stabilizers, antioxidants, preservatives, bacteriostats, pyrogen-free water, etc.
In the present invention, the dosage form of the composition is not particularly limited, and is preferably a solid preparation or a liquid preparation.
Preferably, the dosage form of the composition of the present invention is an oral preparation. Typically, the composition is in the form of an oral aqueous solution.
In the composition of the present invention, the amount of arabinose and sugar alcohol is not particularly limited, and preferably, the weight ratio of sugar alcohol and arabinose is 1:0.5-40, preferably 1:0.5-20, more preferably 1:1-10, more preferably 1:1-8, more preferably 1: 2-6.
In a preferred embodiment, the sugar alcohol is present in the composition in an amount of 10 to 90 wt.%, preferably 20 to 80 wt.%, more preferably 30 to 70 wt.%, based on the total weight of the composition.
In a preferred embodiment, the arabinose is present in the composition in an amount of 10 to 90 wt%, preferably 20 to 80 wt%, more preferably 30 to 70 wt%, based on the total weight of the composition.
In another preferred embodiment of the present invention, the composition further comprises sunflower flower extract. Preferably, the sunflower flower extract is dry extract.
Preferably, the weight ratio of said sugar alcohol to sunflower extract is 1:0.2-20, preferably 1:0.5-10, more preferably 1:0.8-6, more preferably 1:1-5, more preferably 1: 1-3.
Preferably, the weight ratio of the sugar alcohol to the arabinose to the sunflower extract is 1 (1-10): (0.8-6), preferably 1 (1-8): (1-5), more preferably 1 (2-6): (1-3).
In the present invention, the sunflower flower extract is preferably an aqueous extract, a C1-C4 lower alcohol extract or a C1-C4 lower alcohol aqueous extract.
Typically, the sunflower extract according to the invention is prepared by solvent extraction selected from the group consisting of: water, C1-C4 lower alcohol or C1-C4 lower alcohol aqueous solution.
Preferably, the C1-C4 lower alcohol comprises one or more of methanol, ethanol, propanol and butanol.
Typically, the aqueous solution of C1-C4 lower alcohol is 30-95% (v/v) aqueous ethanol, preferably 50-90% (v/v) aqueous ethanol, more preferably 60-85% (v/v) aqueous ethanol, preferably 70-80% (v/v) aqueous ethanol.
Preferably, in the composition of the present invention, the sunflower flower extract is present in an amount of 1-99 wt%, preferably 10-90 wt%, more preferably 20-80 wt%, based on the total weight of the composition.
The compositions of the present invention may be prepared by methods conventional in the art, for example, by simply mixing the components.
Use of
The present invention provides a use of the composition of the invention for use as a laxative and/or for bowel preparation.
Experiments conducted in the examples of the present invention show that the combination of sorbitol and L-arabinose with sorbitol, L-arabinose and sunflower extract has an excellent synergistic effect in relaxing bowel and, therefore, can be used for facilitating excretion and bowel preparation, as well as for electrocoagulation and/or electrosection after bowel preparation.
The experiment of the embodiment of the invention shows that the sunflower extract has the effect of relaxing bowel, can be used as a cathartic and intestinal tract preparation, and has the effects of enhancing and promoting the excretion and intestinal tract preparation of sugar alcohol and L-arabinose.
The main technical effects obtained by the invention comprise:
1. the invention discovers for the first time that the combination of sorbitol and L-arabinose, as well as sorbitol, L-arabinose and sunflower flower extract has excellent synergistic effect on promoting excretion and relaxing bowel, thus being used for treating constipation, playing a role in cathartic and also being used for intestinal preparation and intestinal related surgery (such as high-frequency electrocoagulation and/or high-frequency electrosection) treatment.
2. In the composition, the sorbitol and the L-arabinose have fresh, sweet and cool mouthfeel, so that the composition is comfortable to take, can avoid the feeling that the existing intestine clearing medicaments such as PEG, magnesium sulfate and other chemical medicaments are difficult to swallow, greatly improves the compliance of patients, and improves the compliance of the intestine clearing and intestinal tract preparation of the patients.
Example 1 examination of the Effect of sorbitol, L-arabinose and sunflower extract on mouse excretion production of sunflower extract
Adding 75% ethanol water solution 5 times by weight into sunflower, heating and reflux extracting for 8h, filtering, concentrating the filtrate under reduced pressure, and drying to obtain dry extract, i.e. sunflower extract.
Experimental methods
Experimental animals and their rearing: c57BL/6J mice, Specific Pathogen Free (SPF) grade, male, 6 weeks old; the common feed is D12450-B feed: 67.35 wt% carbohydrate, 19.2 wt% crude protein, 4.3 wt% fat. The temperature of the room is kept at 24-26 ℃ and the humidity is 40-60%.
Constructing a mouse constipation model: the mice are gavaged with loperamide suspension of 9mg/kg. body weight for 2 times/d, the first administration is doubled, and the constipation is established for 8 days continuously.
Experimental investigation:
constipation mice were randomly divided into model group, trial group 1, trial group 2, trial group 3, trial group 4 and trial group 5, with 8 mice per group. In addition, 8 normal healthy non-constipated mice were randomly selected as a blank control group.
The mice in each group were fasted without water prohibition before administration 12 times, and then, the mice in the placebo group, the model group, the test group 1, the test group 2, the test group 3, the test group 4 and the test group 5 were administered with gavage normal saline, sorbitol, L-arabinose, sorbitol + L-arabinose, sunflower flower extract, sorbitol + L-arabinose + sunflower flower extract, and after 0.5h, with ink containing montmorillonite powder (10mg/kg. bw), and the mice in each group were fed water normally. Starting from ink filling, recording the black excrement discharging time of the first grains of each group of animals, and detecting the water content of excrement in 5 hours.
The effect of the mode of administration on bowel movement time, stool grain number and stool weight for the different groups of mice is shown in table 1:
TABLE 1 Effect of the administration of different groups of mice on defecation time, stool size and stool weight (n. 8)
Note: comparing to the model group, "# is P < 0.05," # is P < 0.01; the extract is sunflower flower extract (dry extract), and the dosage is calculated according to the amount of the sunflower flower extract.
As can be seen from Table 1, the blank control group and the model group have significant differences (P < 0.01) in the detection results of the first defecation time, the fecal water content and the fecal weight, which indicates that the constipation model of the mouse is established. Compared with the model group mice, the test group mice 1-5 have the advantages of shortened defecation time, increased water content of excrement and quality of excrement, and the sorbitol, the L-arabinose and the sunflower flower extract have the effects of promoting excretion and relaxing bowel. As can be seen from the data in the test groups 1-3, the combination of sorbitol and L-arabinose had a synergistic effect on facilitating excretion and relaxing bowel compared to the administration of sorbitol, L-arabinose alone. Furthermore, as can be seen from the data in table 1, sorbitol, L-arabinose and sunflower extracts also have excellent synergistic effects on the promotion of excretion and defecation compared to the administration of sorbitol, L-arabinose and sunflower extracts alone, thus being useful for the treatment of constipation, as a laxative, and also for the preparation of intestinal tracts and for the performance of intestinal tract-related operations.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (10)
1. A composition comprising a sugar alcohol and arabinose.
2. The composition of claim 1, wherein the arabinose comprises L-arabinose; and/or
The sugar alcohol comprises one or more of sorbitol and mannitol.
3. The composition according to claim 1, wherein the weight ratio of sugar alcohol to arabinose is from 1:0.5 to 40, preferably from 1:0.5 to 20, more preferably from 1:1 to 10, more preferably from 1:1 to 8, more preferably from 1:2 to 6.
4. The composition of claim 1, wherein said composition further comprises sunflower extract.
5. The composition according to claim 4, wherein the weight ratio of sugar alcohol, arabinose and sunflower extract is 1 (1-10): (0.8-6), preferably 1 (1-8): (1-5), more preferably 1 (2-6): (1-3).
6. The composition of claim 4, wherein said sunflower extract is prepared by solvent extraction selected from the group consisting of: water, C1-C4 lower alcohol or C1-C4 lower alcohol aqueous solution.
7. The composition of claim 6, wherein the C1-C4 lower alcohol comprises one or more of methanol, ethanol, propanol, and butanol.
8. The composition of claim 1, wherein the composition is a pharmaceutical composition, a food composition, or a nutraceutical composition.
9. Use of a composition according to claim 1 for the preparation of a composition for one or more uses selected from the group consisting of: (a) as a laxative; (b) for bowel preparation.
10. Use of a sunflower extract for the preparation of a composition for one or more uses selected from the group consisting of: (i) as a laxative; (ii) for bowel preparation; (iii) it can be used for enhancing excretion and intestinal tract preparation of sugar alcohol and L-arabinose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010851993.9A CN112168855B (en) | 2020-08-21 | 2020-08-21 | A composition for preparing intestinal tract and treating constipation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010851993.9A CN112168855B (en) | 2020-08-21 | 2020-08-21 | A composition for preparing intestinal tract and treating constipation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112168855A true CN112168855A (en) | 2021-01-05 |
| CN112168855B CN112168855B (en) | 2022-06-03 |
Family
ID=73924466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010851993.9A Active CN112168855B (en) | 2020-08-21 | 2020-08-21 | A composition for preparing intestinal tract and treating constipation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112168855B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112089717A (en) * | 2020-08-25 | 2020-12-18 | 唐传生物科技（厦门）有限公司 | Application of arabinose and composition for preparing intestinal tract |
| CN112206236A (en) * | 2020-08-28 | 2021-01-12 | 唐传生物科技（厦门）有限公司 | Application of L-arabinose in inhibiting intestinal gas production of sorbitol |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520202A (en) * | 2012-07-02 | 2014-01-22 | 舒泰神（北京）生物制药股份有限公司 | Pharmaceutical composition for facilitating feces excretion and clearing bowels |
| CN111544436A (en) * | 2020-04-16 | 2020-08-18 | 唐传生物科技（厦门）有限公司 | Intestinal tract preparation pharmaceutical composition for cleaning intestinal tract and preparation method thereof |
-
2020
- 2020-08-21 CN CN202010851993.9A patent/CN112168855B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520202A (en) * | 2012-07-02 | 2014-01-22 | 舒泰神（北京）生物制药股份有限公司 | Pharmaceutical composition for facilitating feces excretion and clearing bowels |
| CN111544436A (en) * | 2020-04-16 | 2020-08-18 | 唐传生物科技（厦门）有限公司 | Intestinal tract preparation pharmaceutical composition for cleaning intestinal tract and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 王昕等: "L-阿拉伯糖在结肠镜检查前肠道准备中的应用", 《中华消化内镜杂志》 * |
| 赵玉玲: "《土单验方治百病》", 30 June 2007, 中国社会出版社 * |
| 陈文: "《功能食品教程》", 31 December 2018, 中国轻工业出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112089717A (en) * | 2020-08-25 | 2020-12-18 | 唐传生物科技（厦门）有限公司 | Application of arabinose and composition for preparing intestinal tract |
| CN112089717B (en) * | 2020-08-25 | 2022-02-22 | 唐传生物科技（厦门）有限公司 | Application of arabinose and composition for preparing intestinal tract |
| CN112206236A (en) * | 2020-08-28 | 2021-01-12 | 唐传生物科技（厦门）有限公司 | Application of L-arabinose in inhibiting intestinal gas production of sorbitol |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112168855B (en) | 2022-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112168855B (en) | A composition for preparing intestinal tract and treating constipation | |
| JP2022123094A (en) | Method for treating mucositis | |
| CN112089717B (en) | Application of arabinose and composition for preparing intestinal tract | |
| KR101228920B1 (en) | A composition comprising of a leaf extract of dendropanax morbifera for treating and preventing intestinal function disorder | |
| KR102416513B1 (en) | Composition for preventing and improving pet constipation and manufacturing method thereof | |
| CN101279022A (en) | Preparation of Simotang enema and suppositorium | |
| KR101899555B1 (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
| CN100471500C (en) | Medicinal composition contg. glucoside of pueravia flower and its application | |
| KR102600312B1 (en) | Composition for preventing or treating irritable bowel syndrome comprising humulus japonicus extract | |
| JP5187935B2 (en) | Wound healing promoting composition containing Rahan fruit extract and application method | |
| JP2005179316A (en) | Composition with constipation ameliorating action | |
| CN115768417A (en) | Muscular atrophy inhibitor | |
| JP2018087175A (en) | Muscular atrophy inhibitor | |
| CN101879201A (en) | Medicine for preventing and curing eperythrozoonosis of pigs, sheep and cows and preparation method thereof | |
| CN112843138A (en) | Traditional Chinese medicine composition for preventing and treating calf damp-heat diarrhea and preparation method and application thereof | |
| CN112870382A (en) | Arabinose and silicone oil type antifoaming agent combination for bowel preparation | |
| CN112315972B (en) | Composition for preparing intestinal tract | |
| EP3943095A1 (en) | Traditional chinese medicine laxative composition for treating constipation, preparation method therefor and application thereof | |
| CN113995809B (en) | Medicine for improving intestinal micro-ecological disorder of children | |
| CN112353837B (en) | Flos puerariae extract and its use | |
| CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
| CN101926846A (en) | Medicinal composition for treating pullorum disease and preparation method thereof | |
| CN111467356B (en) | Pharmaceutical composition containing L-arabinose for treating constipation and application method thereof | |
| EP3697383B1 (en) | Composition for treating constipation | |
| KR102522724B1 (en) | Pharmaceutical composition for preventing, ameliorating or treating inflammatory bowel disease comprising 8-HVA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Lin Weijun Inventor after: Shi Guoliang Inventor after: Chen Xu Inventor after: Wang Yujuan Inventor after: Hong Shiqun Inventor after: Cai Xubin Inventor after: Xiao Shunzhi Inventor after: Guo Zhijian Inventor before: Lin Weijun Inventor before: Shi Guoliang Inventor before: Chen Xu Inventor before: Wang Yujuan Inventor before: Hong Shiqun Inventor before: Cai Xubin Inventor before: Xiao Shunzhi Inventor before: Guo Zhijian |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |